DK2928477T3 - Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis - Google Patents

Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis Download PDF

Info

Publication number
DK2928477T3
DK2928477T3 DK13861008.4T DK13861008T DK2928477T3 DK 2928477 T3 DK2928477 T3 DK 2928477T3 DK 13861008 T DK13861008 T DK 13861008T DK 2928477 T3 DK2928477 T3 DK 2928477T3
Authority
DK
Denmark
Prior art keywords
teletomerase
treat myelofibrosis
imetelstat
inhibitor
inhibitor imetelstat
Prior art date
Application number
DK13861008.4T
Other languages
English (en)
Inventor
Stephen Kelsey
Monic J Stuart
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corp filed Critical Geron Corp
Application granted granted Critical
Publication of DK2928477T3 publication Critical patent/DK2928477T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK13861008.4T 2012-12-07 2013-11-15 Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis DK2928477T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05
PCT/US2013/070437 WO2014088785A1 (en) 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
DK2928477T3 true DK2928477T3 (da) 2019-10-07

Family

ID=50883867

Family Applications (3)

Application Number Title Priority Date Filing Date
DK18196690.4T DK3456333T3 (da) 2012-12-07 2013-11-15 Anvendelse af telomeraseinhibitor imetelstat til behandling af myelodysplastisk syndrom
DK19187756.2T DK3646876T3 (da) 2012-12-07 2013-11-15 Telomeraseinhibitoren imetelstat til behandling af myeloproliferative lidelser og myeloproliferative neoplasmer
DK13861008.4T DK2928477T3 (da) 2012-12-07 2013-11-15 Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK18196690.4T DK3456333T3 (da) 2012-12-07 2013-11-15 Anvendelse af telomeraseinhibitor imetelstat til behandling af myelodysplastisk syndrom
DK19187756.2T DK3646876T3 (da) 2012-12-07 2013-11-15 Telomeraseinhibitoren imetelstat til behandling af myeloproliferative lidelser og myeloproliferative neoplasmer

Country Status (33)

Country Link
EP (3) EP2928477B1 (da)
JP (5) JP6433911B2 (da)
KR (2) KR20230028590A (da)
CN (2) CN104936602B (da)
AP (1) AP2015008504A0 (da)
AU (3) AU2013356533B2 (da)
BR (1) BR112015013260A2 (da)
CA (2) CA3188494A1 (da)
CL (2) CL2015001530A1 (da)
CY (2) CY1122169T1 (da)
DK (3) DK3456333T3 (da)
EA (1) EA032973B1 (da)
ES (2) ES2789176T3 (da)
HK (2) HK1210940A1 (da)
HR (2) HRP20191784T1 (da)
HU (2) HUE049858T2 (da)
IL (2) IL239266B (da)
LT (2) LT2928477T (da)
MA (2) MA38193B1 (da)
ME (1) ME03538B (da)
MX (3) MX2015007169A (da)
MY (1) MY180634A (da)
NZ (1) NZ708920A (da)
PH (1) PH12015501282A1 (da)
PL (2) PL3456333T3 (da)
PT (2) PT3456333T (da)
RS (2) RS60401B1 (da)
SG (3) SG10202103341SA (da)
SI (2) SI3456333T1 (da)
TN (1) TN2015000249A1 (da)
UA (2) UA117116C2 (da)
WO (1) WO2014088785A1 (da)
ZA (2) ZA201504124B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054463T2 (hu) 2004-07-02 2021-09-28 Geron Corp Védett 3'-amino 5'-foszforamidit nukleozid monomerek szintézise
AU2014346840B2 (en) * 2013-11-06 2020-02-06 Mayo Foundation For Medical Education And Research Methods and materials for treating hematological malignancies
SI3286203T1 (sl) 2015-04-23 2020-10-30 Geron Corporation Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
WO2019023667A1 (en) 2017-07-28 2019-01-31 Janssen Biotech, Inc. METHODS OF TREATING MYELODYSPLASTIC SYNDROME
CA3098606A1 (en) * 2018-04-30 2019-11-07 Kartos Therapeutics, Inc. Methods of treating cancer
CN115666588A (zh) * 2019-11-04 2023-01-31 美国杰龙生物医药公司 Janus激酶抑制剂和端粒酶抑制剂用于治疗骨髓增殖性肿瘤的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
EP0951568A1 (en) 1996-12-20 1999-10-27 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2515000A1 (en) * 2003-01-31 2004-08-19 Jessie L.-S. Au Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
KR101298493B1 (ko) 2003-09-09 2013-08-21 제론 코포레이션 텔로머라제 억제를 위한 변형 올리고뉴클레오티드
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
HUE054463T2 (hu) 2004-07-02 2021-09-28 Geron Corp Védett 3'-amino 5'-foszforamidit nukleozid monomerek szintézise
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
ATE553198T1 (de) 2005-04-15 2012-04-15 Geron Corp Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
CA2892907A1 (en) 2014-06-12
AU2020267142A1 (en) 2020-12-03
LT3456333T (lt) 2020-06-25
MA45504B1 (fr) 2021-10-29
UA126015C2 (uk) 2022-08-03
CN104936602A (zh) 2015-09-23
CA3188494A1 (en) 2014-06-12
AU2018282364A1 (en) 2019-05-23
JP2022050537A (ja) 2022-03-30
ES2744790T3 (es) 2020-02-26
RS60401B1 (sr) 2020-07-31
LT2928477T (lt) 2019-10-10
WO2014088785A1 (en) 2014-06-12
MY180634A (en) 2020-12-03
JP7288098B2 (ja) 2023-06-06
HRP20191784T1 (hr) 2019-12-27
EP3456333B1 (en) 2020-04-01
IL280144A (en) 2021-03-01
ZA201504124B (en) 2017-05-31
ES2789176T3 (es) 2020-10-26
PL2928477T3 (pl) 2020-03-31
UA117116C2 (uk) 2018-06-25
EP3456333B8 (en) 2020-05-13
EA201590878A1 (ru) 2016-04-29
SI3456333T1 (sl) 2020-10-30
CY1123206T1 (el) 2021-10-29
DK3456333T3 (da) 2020-05-18
PT2928477T (pt) 2019-10-25
CL2015001530A1 (es) 2016-03-28
KR102294819B1 (ko) 2021-09-01
MX2020003276A (es) 2020-07-20
HK1212226A1 (en) 2016-06-10
PT3456333T (pt) 2020-06-01
JP6998191B2 (ja) 2022-02-04
EP3646876B1 (en) 2024-02-14
SG10202103341SA (en) 2021-05-28
ME03538B (me) 2020-07-20
RS59363B1 (sr) 2019-11-29
SG11201504383TA (en) 2015-07-30
EP2928477A4 (en) 2016-09-21
BR112015013260A2 (pt) 2018-02-06
PH12015501282B1 (en) 2015-08-24
EP2928477A1 (en) 2015-10-14
AP2015008504A0 (en) 2015-06-30
JP2018035196A (ja) 2018-03-08
NZ708920A (en) 2020-08-28
JP2022179684A (ja) 2022-12-02
IL239266A0 (en) 2015-07-30
TN2015000249A1 (en) 2016-10-03
AU2013356533A1 (en) 2014-06-12
CA2892907C (en) 2023-03-21
CN104936602B (zh) 2020-07-17
MX2022015437A (es) 2023-01-11
EP3456333A1 (en) 2019-03-20
SG10201802926XA (en) 2018-05-30
DK3646876T3 (da) 2024-05-06
ZA202108991B (en) 2023-05-31
PH12015501282A1 (en) 2015-08-24
EA032973B1 (ru) 2019-08-30
KR20210107906A (ko) 2021-09-01
MA38193B1 (fr) 2018-12-31
MA45504A1 (fr) 2020-05-29
MA38193A1 (fr) 2017-12-29
KR20150091130A (ko) 2015-08-07
CY1122169T1 (el) 2020-11-25
CL2017002156A1 (es) 2018-05-04
HUE049858T2 (hu) 2020-11-30
MX2015007169A (es) 2016-03-31
JP6433911B2 (ja) 2018-12-05
HK1210940A1 (en) 2016-05-13
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
EP2928477B1 (en) 2019-07-24
JP2016504307A (ja) 2016-02-12
EP3646876A1 (en) 2020-05-06
WO2014088785A8 (en) 2015-07-16
AU2013356533B2 (en) 2018-09-27
CN111617252A (zh) 2020-09-04
KR20230028590A (ko) 2023-02-28
PL3456333T3 (pl) 2020-09-21
NZ748134A (en) 2020-10-30
IL239266B (en) 2019-11-28
JP2020041001A (ja) 2020-03-19
SI2928477T1 (sl) 2019-11-29

Similar Documents

Publication Publication Date Title
SMT201700109B (it) Inibitori di istone demetilasi
CO7030959A2 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
DK2906696T4 (da) Fremgangsmåder til modulering af c9orf72-ekspression
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
DK2885010T3 (da) Fremgangsmåder til behandling med tauopati
CO7010824A2 (es) Inhibidores de aplicación viral
DK2769301T3 (da) Transformation af ikke-sammenhængende instruktionsspecifikatorer til sammenhængende instruktionsspecifikatorer
DK2854769T3 (da) Fremgangsmåder til behandling af artritis
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
DK2833884T3 (da) Anvendelse af ccr3-inhibitorer
DK2928477T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
DK2897611T3 (da) Fremgangsmåder til behandling af hepatitis c
DK2985275T3 (da) Fremgangsmåde til oprensning af beta-hydroxy-beta-methylsmørsyre
DK2906219T3 (da) Orvepitant til behandling af kronisk pruritus
DK2705847T3 (da) Sammensætning til behandling af psoriasis
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
DK2888228T3 (da) Inhibitorer af CD40-TRAF6 interaktion
DK2838850T3 (da) Oprensning af titantetrachlorid
FR2994974B1 (fr) Distillation reactive des dso
CR20130603A (es) Compuestos novedosos como inhibidores de diacilglicerol
DK2825636T3 (da) Behandling af sædceller
DK2500036T3 (da) MET-hæmmere til øgning af virkningen af radioterapi
DK3590960T3 (da) Igg-stimuleret remyelinisering af perifere nerver
FR2997080B1 (fr) Inhibiteurs de neprilysine
DK3473276T3 (da) Teknikker til behandling af abscesser